Evolent Health (EVH)
(Delayed Data from NYSE)
$19.74 USD
+0.49 (2.55%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $19.75 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Evolent Health, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -113.04 | -19.16 | -37.60 | -334.25 | -305.58 |
Depreciation/Amortization & Depletion | 138.17 | 92.55 | 91.12 | 312.55 | 275.81 |
Net Change from Assets/Liabilities | 38.52 | -58.49 | -13.65 | -55.32 | 0.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 78.93 | -26.45 | -1.13 | 60.79 | -13.20 |
Net Cash From Operating Activities | 142.58 | -11.55 | 38.75 | -16.23 | -42.65 |
Property & Equipment | -28.75 | -38.36 | -24.98 | -29.47 | -35.53 |
Acquisition/ Disposition of Subsidiaries | -388.25 | -248.11 | -49.01 | -0.30 | -8.58 |
Investments | 0.87 | 5.55 | 11.72 | 133.38 | -91.13 |
Other Investing Activities | 0.58 | 21.81 | 46.49 | 157.47 | -46.40 |
Net Cash from Investing Activities | -415.54 | -259.12 | -15.79 | 261.07 | -181.63 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 180.52 | 4.45 | 13.29 | 2.58 | 1.09 |
Issuance (Repayment) of Debt | 183.29 | 219.74 | -0.43 | 13.46 | 62.65 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -18.79 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -63.68 | -92.65 | -42.41 | -27.90 | -99.29 |
Net Cash from Financing Activities | 281.34 | 131.54 | -29.55 | -11.86 | -35.55 |
Effect of Exchange Rate Changes | -0.08 | -0.66 | -0.05 | 0.07 | 0.03 |
Net Change In Cash & Equivalents | 8.30 | -139.78 | -6.64 | 233.05 | -259.79 |
Cash at Beginning of Period | 215.16 | 354.94 | 361.58 | 128.53 | 388.33 |
Cash at End of Period | 223.46 | 215.16 | 354.94 | 361.58 | 128.53 |
Diluted Net EPS | -1.28 | -0.20 | -0.44 | -3.94 | -3.67 |
Fiscal Year End for Evolent Health, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -17.28 | -113.04 | -79.63 | -54.31 | -19.98 |
Depreciation/Amortization & Depletion | 31.59 | 138.17 | 104.73 | 69.00 | 32.48 |
Net Change from Assets/Liabilities | -38.34 | 38.52 | -26.61 | -61.11 | 29.46 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 28.94 | 78.93 | 54.71 | 39.10 | -49.93 |
Net Cash From Operating Activities | 4.91 | 142.58 | 53.20 | -7.32 | -7.97 |
Property & Equipment | -5.35 | -28.75 | -22.69 | -15.90 | -9.06 |
Acquisition/ Disposition of Subsidiaries | -1.39 | -388.25 | -388.25 | -388.25 | -386.72 |
Investments | -3.00 | 0.87 | 0.87 | 0.80 | 0.79 |
Other Investing Activities | 0.00 | 0.58 | 0.58 | 0.00 | 0.00 |
Net Cash from Investing Activities | -9.73 | -415.54 | -409.49 | -403.35 | -394.99 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.06 | 180.52 | 177.18 | 172.65 | 169.58 |
Issuance (Repayment) of Debt | -0.53 | 183.29 | 208.56 | 218.56 | 218.83 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -5.08 | -18.79 | -13.63 | -8.54 | -3.65 |
Other Financing Activities | 19.43 | -63.68 | -6.42 | 20.38 | -5.03 |
Net Cash from Financing Activities | 14.88 | 281.34 | 365.69 | 403.06 | 379.73 |
Effect of Exchange Rate Changes | -0.04 | -0.08 | -0.06 | 0.05 | 0.05 |
Net Change In Cash & Equivalents | 10.02 | 8.30 | 9.34 | -7.56 | -23.19 |
Cash at Beginning of Period | 223.46 | 215.16 | 215.16 | 215.16 | 215.16 |
Cash at End of Period | 233.48 | 223.46 | 224.50 | 207.60 | 191.97 |
Diluted Net EPS | -0.22 | -0.37 | -0.30 | -0.37 | -0.24 |